European Journal of Nuclear Medicine and Molecular Imaging最新文献

{"title":"Exendin-4 imaging based on gastrointestinal GLP-1R targets for IBD diagnosis and efficacy assessment","authors":"Xiaochen Li, Yang Liu, Zizhen Zhang, Wangxi Hai, Yu Pan, Yifan Zhang","doi":"10.1007/s00259-025-07197-z","DOIUrl":"https://doi.org/10.1007/s00259-025-07197-z","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Purpose</h3><p>Diagnosis of inflammatory bowel disease (IBD) involves history-taking and invasive procedures that primarily evaluate localized intestinal structures. Notably, glucagon-like peptide 1 (GLP-1) and its receptor (GLP-1R) have been established as potent participants in various inflammatory diseases. This study aimed to investigate the potential of molecular imaging targeting GLP-1R in the study of gastrointestinal physiology and disease.</p><h3 data-test=\"abstract-sub-heading\">Methods</h3><p>Using dextran sulfate sodium (DSS)-induced IBD rats (<i>n</i> = 6), changes in GLP-1R expression in the gastrointestinal tract before and after DSS induction were determined by quantitative micro-PET/CT. Dynamic changes in GLP-1R expression after liraglutide treatment were also assessed in IBD rats. Transcription of GLP-1R and inflammatory factors in duodenal and colonic tissues were measured and subjected to correlation analysis.</p><h3 data-test=\"abstract-sub-heading\">Results</h3><p>In normal rats, GLP-1R was highly concentrated in the proximal duodenum, with a higher distribution density near the distal end of the colonic segment. Proximal duodenal uptake of [⁶⁸Ga]Ga-NOTA-MAL-Cys³⁹-exendin-4 was significantly increased after DSS induction compared with controls. The increased colonic uptake closely correlated with the histopathologic score of epithelial injury. In IBD rats treated with liraglutide, proximal duodenal uptake was reduced. In addition, Western blotting and quantitative PCR confirmed changes in GLP-1R expression during disease progression.</p><h3 data-test=\"abstract-sub-heading\">Conclusion</h3><p>These findings underscore the role of molecular imaging in assessing dynamic changes in GLP-1R expression and its potential for improving diagnostic and therapeutic strategies for gastrointestinal disorders like IBD. It supports using Brunner’s glands as a key site to observe GLP-1R expression, advancing research on the GLP-1R/GLP-1RA axis in complex gastrointestinal conditions.</p><h3 data-test=\"abstract-sub-heading\">Graphical Abstract</h3>","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"6 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143766743","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic value of [18F]fluorodeoxyglucose-PET/MRI(CT) novel interpretation criteria (IMPeTUs) in multiple myeloma","authors":"Miao Zhang, Tangjia Cai, Shiwei Jin, Xinyun Huang, Yuting Gao, Xiaoyue Chen, Wanyan Ouyang, Yi Tao, Yuanfang Liu, Yan Wang, Hongping Meng, Jian Li, Xiaozhu Lin, Kuangyu Shi, Jin Wang, Xiaoyi Ding, Jian-Qing Mi, Biao Li","doi":"10.1007/s00259-025-07219-w","DOIUrl":"https://doi.org/10.1007/s00259-025-07219-w","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Purpose</h3><p>[¹⁸F]fluorodeoxyglucose (FDG)-PET is a powerful tool to evaluate prognosis in multiple myeloma (MM). The development of systematic and reproducible standard interpretation criteria is crucial for the effective application of FDG-PET in MM. A new set of criteria—Italian Myeloma criteria for PET Use (IMPeTUs)—has standardized PET evaluation in MM. However, the prognostic value of IMPeTUs score remains unknown.</p><h3 data-test=\"abstract-sub-heading\">Methods</h3><p>A total of 58 patients with newly diagnosed multiple myeloma (NDMM) who underwent both [¹⁸F]FDG-PET/MRI and PET/CT examinations at diagnosis were enrolled (ChiCTR1900022597). All patients completed a 42-month follow-up. The prognostic value of the PET/MRI (or PET/CT) IMPeTUs score in predicting progression-free (PFS) and overall (OS) survival was compared with that of individual laboratory parameters and the maximum standardized uptake value (SUVmax). Kaplan-Meier method was used for survival analysis. Univariate and multivariate analyses of prognostic factors were conducted using Cox regression.</p><h3 data-test=\"abstract-sub-heading\">Results</h3><p>ROC curves demonstrated that the area under the curve for the PET/MRI IMPeTUs score was 0.760, exceeding that of the PET/CT IMPeTUs score (0.711), PET/CT BM SUVmax (0.649), PET/MRI BM SUVmax (0.575), bone marrow plasma cells (0.500), and β2-microglobulin (0.501). Univariate analysis and Kaplan-Meier analysis showed that a PET/MRI IMPeTUs score ≥ 13 and PET/CT IMPeTUs score ≥ 10 were significantly associated with worse PFS. Cox multivariate analysis showed that a PET/MRI IMPeTUs score ≥ 13 was an independent risk factor for PFS.</p><h3 data-test=\"abstract-sub-heading\">Conclusion</h3><p>IMPeTUs standardized [¹⁸F]FDG-PET/MRI and PET/CT readings in MM. The IMPeTUs score is crucial for predicting MM prognosis, performing better than SUVmax and clinical indicators.</p><h3 data-test=\"abstract-sub-heading\">Clinical trial registration</h3><p>ChiCTR1900022597, Registered on 18 April 2019.</p>","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"96 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143767079","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[177Lu]Lu-EDTMP —a bone pain palliating agent: pharmacokinetics, biodistribution, safety profile and clinical evaluation in osseous metastatic patients","authors":"Shabana Saeed, Diana Paez, Enrique Estrada Lobato, Roberto C. Delgado Bolton, Ghazal Jameel, Farida Qureshi, Olivier Pellet, Anita Brink, Adrian Soto, Anna Grigoryan, Peter Knoll, Francesco Giammarile","doi":"10.1007/s00259-025-07218-x","DOIUrl":"https://doi.org/10.1007/s00259-025-07218-x","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Background</h3><p>[¹⁷⁷Lu]Lu-EDTMP has emerged as a promising radiopharmaceutical for the palliation of pain caused by osseous metastases. This phase I/II study comprehensively evaluate the pharmacokinetics, biodistribution, clinical efficacy, and safety profile of [¹⁷⁷Lu]Lu-EDTMP, in patients with skeletal metastases from breast and prostate cancer.</p><h3 data-test=\"abstract-sub-heading\">Methods</h3><p>A total of 27 patients with skeletal metastases were included in the study. Pharmacokinetics and biodistribution were analyzed in 17 patients through whole-body gamma camera imaging and quantification at multiple time points. Clinical efficacy and safety were evaluated in 18 patients receiving either low (1.3 GBq) or high (2.6 GBq) administered activity. Pain palliation was assessed using visual analog scale scores, analgesic usage (frequency and type), mobility scores, and Karnofsky performance status. The safety profile was determined through hematological and biochemical monitoring over 12 weeks.</p><h3 data-test=\"abstract-sub-heading\">Results</h3><p>[¹⁷⁷Lu]Lu-EDTMP demonstrated rapid blood clearance, with negligible residual activity at 24 h. Urinary excretion accounted for over 30% of administered activity at 24 h. Bone uptake increased progressively to over 70%.</p><p>Scintigraphy revealed selective uptake in metastases, improving lesion-to-bone and lesion-to-soft tissue ratios. Both low (1.3 GBq) and high (2.6 GBq) activity groups showed significant pain relief, with faster, longer-lasting effects in the high-dose group, reducing opioid/NSAID use. No Grade III/IV myelotoxicity or major renal/hepatic events occurred.</p><h3 data-test=\"abstract-sub-heading\">Conclusion</h3><p>[¹⁷⁷Lu]Lu-EDTMP is a safe and effective bone pain palliation agent, with favorable pharmacokinetics, targeted skeletal uptake, and minimal toxicity. These findings support its potential use as an alternative radiopharmaceutical for pain palliation in patients with skeletal metastases.</p><h3 data-test=\"abstract-sub-heading\">Clinical trial number</h3><p>Not applicable.</p>","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"183 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143758520","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Vancomycin-based tracers guiding in situ visualization of bacteria on osteosynthesis devices and surgical debridement","authors":"Gerbren B. Spoelstra, Philip H. Elsinga, Jan Maarten van Dijl, Johannes H. van Snick, Ben L. Feringa, Andor W. J. M. Glaudemans, Bas Keizers, Schelto Kruijff, Wiktor Szymanski, Marleen van Oosten, Frank F. A. IJpma","doi":"10.1007/s00259-025-07249-4","DOIUrl":"https://doi.org/10.1007/s00259-025-07249-4","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Purpose</h3><p>Bacterial infections associated with musculoskeletal injuries are challenging to detect and distinguish from sterile inflammation. Here we present the combined first-time application of a bacteria-targeted positron emission tomography (PET) tracer and a near-infrared fluorescent tracer to detect infected osteosynthesis implants and guide surgical treatment.</p><h3 data-test=\"abstract-sub-heading\">Methods</h3><p>To this end, osteosynthesis plates covered with bacterial biofilm and pre-incubated with [¹⁸F]PQ-VE1-vancomycin for PET imaging and/or vancomycin-IRDye800CW for optical imaging were fixed to post-mortem human tibiae and femora. PET/CT and fluorescence imaging were used to quantify the bacterial load before and after surgical debridement.</p><h3 data-test=\"abstract-sub-heading\">Results</h3><p>Pre-debridement, PET imaging showed a significant 2.2-fold higher tracer uptake on biofilm-covered plates compared to plates without biofilm (<i>p</i> &lt; 0.001). Post-debridement, the PET signal was marginal, demonstrating effective biofilm removal. Fluorescence-guided surgery enabled real-time visualization and removal of bacterial biofilms.</p><h3 data-test=\"abstract-sub-heading\">Conclusion</h3><p>Combined preoperative PET and intraoperative fluorescence imaging with vancomycin-based tracers allows noninvasive detection and real-time infection management, as demonstrated by these preliminary findings.</p>","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"33 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143758515","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The relation between stress-related neural activity assessed by brain 18F-FDG-PET/CT and cardiovascular outcomes: a systematic review and meta-analysis","authors":"Xinyuan Zhang, Hengxin Li, Xiaoyu Niu, Hang Fu, Rong Xu, Ke Xu, Weifeng Yuan, Ting Xu, Jiangyao Zeng, Ziqi Zhou, Yu Song, Suming Zhang, Yingkun Guo, Shan Huang, Huayan Xu","doi":"10.1007/s00259-025-07217-y","DOIUrl":"https://doi.org/10.1007/s00259-025-07217-y","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Purpose</h3><p>Our study aims to investigate the associations between stress-related neural activity (SNA), a quantified imaging biomarker in processing stress responses assessed by ¹⁸F-FDG-PET/CT, and cardiovascular (CV) outcomes based on available evidence.</p><h3 data-test=\"abstract-sub-heading\">Methods</h3><p>We searched databases from inception to December 1, 2024. Studies assessing the associations between SNA, as quantified by measuring FDG uptake values in the amygdala using ¹⁸F-FDG-PET/CT, and CV outcomes were included. Risk of bias was evaluated using the Newcastle–Ottawa Scale. Random-effects model was implemented for pooled effect sizes (ESs) and heterogeneity evaluation.</p><h3 data-test=\"abstract-sub-heading\">Results</h3><p>Ten studies with 3523 patients with ¹⁸F-FDG-PET/CT were included in our analysis (mean age: 58.5 years; 48.9% female). The ESs included in the analysis comprised hazard ratios (HR) and standardized mean differences (SMD). Among the studies reporting HR, 192 (11.5%) patients experienced composite adverse CV events during a mean follow-up period of 3.8 years. SNA significantly correlated with an increased risk of composite adverse CV events (pooled adjusted HR: 1.61, 95% confidence interval [CI]: 1.12, 2.32). Among the studies reported SMD, individuals experienced composite adverse CV events had significantly higher SNA values than those who did not (Hedges’s g = 0.55, 95% CI: 0.14, 0.96).</p><h3 data-test=\"abstract-sub-heading\">Conclusions</h3><p>SNA, as a noninvasive quantified indicator of processing stress responses assessed by brain ¹⁸F-FDG-PET/CT, is associated with an increased risk of CV outcomes. Further research is warranted to validate these findings and to investigate the clinical utility of SNA across various demographic groups.</p>","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"16 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143758087","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"External validation of nomograms including PSMA PET information for the prediction of lymph node involvement of prostate cancer","authors":"Tessa D. Van Bergen, Arthur J. A. T. Braat, Rick Hermsen, Joris G. Heetman, Lieke Wever, Jules Lavalaye, Maarten Vinken, Clinton D. Bahler, Mark Tann, Claudia Kesch, Tugce Telli, Peter Ka-Fung Chiu, Kwan Kit Wu, Fabio Zattoni, Laura Evangelista, Francesco Ceci, Marcin Miszczyk, Pawel Rajwa, Francesco Barletta, Giorgio Gandaglia, Jean-Paul A. Van Basten, Matthijs J. Scheltema, Harm H. E. Van Melick, Roderick C. N. Van den Bergh, Cornelis A. T. Van den Berg, Giancarlo Marra, Timo F. W. Soeterik","doi":"10.1007/s00259-025-07241-y","DOIUrl":"https://doi.org/10.1007/s00259-025-07241-y","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Background</h3><p>Novel nomograms predicting lymph node involvement (LNI) of prostate cancer (PCa) including PSMA PET information have been developed. However, their predictive accuracy in external populations is still unclear.</p><h3 data-test=\"abstract-sub-heading\">Purpose</h3><p>To externally validate four LNI nomograms including PSMA PET parameters (three Muehlematter models and the Amsterdam-Brisbane-Sydney model) as well as the Briganti 2012 and MSKCC nomograms.</p><h3 data-test=\"abstract-sub-heading\">Methods</h3><p>Patients with histologically confirmed PCa undergoing preoperative MRI and PSMA PET/CT before radical prostatectomy (RP) and extended pelvic lymph node dissection (ePLND) were included. Model discrimination (AUC), calibration and net benefit using decision curve analysis were determined for each nomogram.</p><h3 data-test=\"abstract-sub-heading\">Results</h3><p>A total of 437 patients were included, comprising 0.7% with low-risk disease, 39.8% with intermediate-risk disease, and 59.5% with high-risk disease. Among them, 86 out of 437 (19.7%) had pN1 disease. The sensitivity and specificity of PSMA PET/CT for the detection of LNI were 47.7% (95% CI: 36.8–58.7) and 95.4% (95% CI: 92.7–97.4), respectively. Among predictive models, the Amsterdam-Brisbane-Sydney model achieved the highest discrimination (AUC: 0.81, 95% CI: 0.76–0.86), followed by Muehlematter Model 1 (AUC: 0.79, 95% CI: 0.74–0.85), both with good calibration but slight systematic overestimation of risks across all thresholds. The MSKCC and Briganti 2012 models had AUCs of 0.68 (95% CI: 0.61–0.74) and 0.67 (95% CI: 0.61–0.73), respectively, and both had moderate calibration. Decision curve analysis indicated that the Amsterdam-Brisbane-Sydney model provided superior net benefit across thresholds of 5–20%, followed by the Muehlematter Model 1 nomogram showing benefit in the 14–20% range. Using thresholds of 8% for the Amsterdam-Brisbane-Sydney nomogram and 15% for Muehlematter Model 1, ePLND could be spared in 15% and 16% of patients, respectively, without missing any LNI cases.</p><h3 data-test=\"abstract-sub-heading\">Conclusion</h3><p>External validation of the Muehlematter Model 1 and Amsterdam-Brisbane-Sydney nomograms for predicting LNI confirmed their strong model discrimination, moderate calibration, and good clinical utility, supporting their reliability as tools to guide clinical decision-making.</p>","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"23 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143758141","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"SUV normalisation and reference tissue selection for [1⁸F]mFBG PET-CT in paediatric and adult patients","authors":"Atia Samim, Diederik P. D. Suurd, Rob van Rooij, Max M. van Noesel, Marnix G. E. H. Lam, Arthur J. A. T. Braat, Nelleke Tolboom, Lise Borgwardt, Godelieve A. M. Tytgat, Bart de Keizer","doi":"10.1007/s00259-025-07242-x","DOIUrl":"https://doi.org/10.1007/s00259-025-07242-x","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Purpose</h3><p><i>Meta</i>-[¹⁸F]fluorobenzylguanidine ([¹⁸F]mFBG) PET-CT is a novel imaging modality for norepinephrine transporter-expressing tumours, such as neuroblastoma and phaeochromocytoma, enabling quantitative assessment and improved diagnostic accuracy compared to <i>meta</i>-[¹²³I]iodobenzylguanidine ([¹²³I]mIBG) scintigraphy. This study aims to: 1) Identify the optimal standardised uptake value (SUV) normalisation method: body weight (BW) or lean body mass (LBM); 2) Determine the most stable reference tissue with SUV uptake below pathological levels.</p><h3 data-test=\"abstract-sub-heading\">Methods</h3><p>We analysed 63 [¹⁸F]mFBG PET-CTs from 35 patients (20 paediatric neuroblastoma, 15 adult phaeochromocytoma). SUV_mean was measured in the liver, blood pool, bone marrow, and muscle, normalised using BW (SUVBW), LBM via James (SUVLBMJames), and LBM via Janmahasatian (SUVLBMJanma). Variability of SUVs and their correlation with weight were assessed.</p><h3 data-test=\"abstract-sub-heading\">Results</h3><p>LBM-based normalisation reduced SUV variability compared to BW-based normalisation. Bone marrow demonstrated the lowest variability and least weight dependency (r² 0.45 for SUVBW versus 0.31 for SUVLBMJanma). The liver had the highest SUVs, increasing the risk of false negatives if used as reference tissue, while the blood pool had the lowest SUVs, raising the risk of false positives. Muscle showed relatively stable SUVs with increasing weight but higher variability than bone marrow.</p><h3 data-test=\"abstract-sub-heading\">Conclusion</h3><p>LBM-based SUV normalisation reduces weight dependency for [¹⁸F]mFBG PET-CT. Bone marrow is the most reliable reference tissue due to its low variability and balanced SUVs, while muscle may serve as an alternative if diffuse bone marrow uptake is present. These findings support standardising LBM-adjusted SUV methods and using bone marrow as the primary reference tissue to enhance diagnostic accuracy.</p><p>Clinical trial registration: <b>EudraCT Number</b>: 2019–003713-33; <b>EU Clinical Trials Number</b>: 2024–513622-35–00.</p>","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"58 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143758517","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bacteria-targeted imaging using vancomycin-based positron emission tomography tracers can distinguish infection from sterile inflammation.","authors":"G B Spoelstra, L M Braams, F F A IJpma, M van Oosten, B L Feringa, W Szymanski, P H Elsinga, Jan Maarten van Dijl","doi":"10.1007/s00259-024-06997-z","DOIUrl":"10.1007/s00259-024-06997-z","url":null,"abstract":"<p><strong>Introduction: </strong>Bacterial infections pose major challenges in medicine. To guide effective infection treatment, faster and more accurate diagnostic modalities are needed. Bacteria-targeted molecular imaging can meet these needs. The present study was aimed at the in vivo evaluation of two ¹⁸F-vancomycin-based PET tracers, for detection of deep-seated Gram-positive bacterial infections. These tracers were bench-marked against the current standard of care, [¹⁸F]FDG.</p><p><strong>Methods: </strong>The potential of [¹⁸F]BODIPY-FL-vancomycin and [¹⁸F]PQ-VE1-vancomycin ([4+2]photocycloadduct of 9,10-phenanthrenequinone-vancomycin and [¹⁸F]fluorinated vinyl ether) to distinguish bacterial infections from sterile inflammation was evaluated in a murine myositis model. Tracer specificity was assessed by infecting mice either with the Gram-positive bacterium Staphylococcus aureus (n = 12) or the Gram-negative bacterium Escherichia coli (n = 12). The contralateral leg was injected with Cytodex beads to induce sterile inflammation, or with phosphate-buffered saline for control. In parallel, mice were imaged with [¹⁸F]FDG (n = 12). Dynamic positron emission tomography (PET) measurements, biodistribution analyses, and immunohistopathology were performed to determine tracer distribution and bacterial burden.</p><p><strong>Results: </strong>Both ¹⁸F-vancomycin-PET tracers accumulated at sites of infection, but not at sites of sterile inflammation, in contrast to [¹⁸F]FDG. The tracers exhibited distinct biodistribution profiles, with [¹⁸F]BODIPY-FL-vancomycin being cleared more rapidly. Both ¹⁸F-vancomycin-PET tracers displayed significant target to non-target ratios of 2.95 for [¹⁸F]BODIPY-FL-vancomycin and 1.48 for [¹⁸F]PQ-VE1-vancomycin.</p><p><strong>Conclusion: </strong>Vancomycin-based PET is a potentially attractive approach to distinguish Gram-positive bacterial infections from sterile inflammation.</p>","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":" ","pages":"1878-1889"},"PeriodicalIF":8.6,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11928434/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142750306","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluating gray matter heterotopia with Florbetapir and Flortaucipir pet: a case report","authors":"Xiaojiao Xiang, Zhenchun Xu, Qiaoqiao Shu, Yue Feng, Liang Cai","doi":"10.1007/s00259-025-07234-x","DOIUrl":"https://doi.org/10.1007/s00259-025-07234-x","url":null,"abstract":"","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"58 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143737014","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prospective comparison of 18F-PSMA-1007 PET/CT and MRI with histopathology as the reference standard for intraprostatic tumour detection and T-staging of high-risk prostate cancer","authors":"Aino Kivikallio, Simona Malaspina, Irena Saarinen, Marko Seppänen, Mikael Anttinen, Ivan Jambor, Janne Verho, Jukka Kemppainen, Hannu J. Aronen, Peter J. Boström, Otto Ettala, Pekka Taimen","doi":"10.1007/s00259-025-07208-z","DOIUrl":"https://doi.org/10.1007/s00259-025-07208-z","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Purpose</h3><p>To prospectively compare the ability of ¹⁸F-PSMA-1007 PET/CT and whole-body MRI (WBMRI) with DWI to detect prostate cancer (PCa) lesions and assess their local stage. Additionally, to evaluate the correlation between PSMA uptake on PET/CT and PSMA expression as assessed by immunohistochemistry.</p><h3 data-test=\"abstract-sub-heading\">Methods</h3><p>Men with newly diagnosed unfavourable intermediate or high-risk PCa underwent ¹⁸F-PSMA-1007 PET/CT and WBMRI with DWI before robot-assisted laparoscopic prostatectomy. Diagnostic accuracy for intraprostatic tumour localization, seminal vesicle invasion (SVI), and extraprostatic extension (EPE) was evaluated using whole-mount prostatectomy specimens as the reference standard. SUVmax was compared with immunohistochemical PSMA staining intensity quantified using QuPath software.</p><h3 data-test=\"abstract-sub-heading\">Results</h3><p>19 patients with 39 intraprostatic lesions in histopathology were included. The overall lesion detection rates for PET/CT were 84.6% and 82.1% for two independent readers, compared to 74.4% and 46.2% for MRI readers. The detection rates of index lesions were 94.7% for PET/CT and 74.0–84.0% for MRI, whereas those of non-index lesions were 70.0–75.0% for PET/CT and 20.0–65.0% for MRI. For detecting EPE, AUC values were 0.500-0.591 for PET/CT and 0.648–0.682 for MRI. For detecting SVI, AUC values ranged from 0.629 to 0.700 across both modalities. SUVmax showed a weak correlation with immunohistochemical expression of PSMA multiplied by lesion diameter (Spearman’s ρ = 0.427, <i>p</i> = 0.013). Lesion diameters measured using 30% and 40% of SUVmax, as well as prostate SUVbackground x2, showed the closest agreement with histopathological measurements.</p><h3 data-test=\"abstract-sub-heading\">Conclusion</h3><p>¹⁸F-PSMA-1007 PET/CT demonstrated high sensitivity in localizing intraprostatic carcinoma lesions but seemed inferior to WBMRI in detecting EPE. PSMA uptake appears to depend on both PSMA expression and lesion size. These findings highlight the complementary roles of PET/CT and MRI in the detection and tumor staging of PCa.</p><h3 data-test=\"abstract-sub-heading\">Clinical trial registration</h3><p>Clinicaltrials.gov ID: NCT03537391. Registered 25 May 2018.</p>","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"36 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143737069","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}